Surescripts Acquires Health IT Vendor to Advance ePrescribing HIE

Surescripts, a health information exchange (HIE) network, has acquired ActiveRADAR, a health IT vendor that identifies therapeutic alternatives for prescriptions.

Surescripts health information network connects more than two million healthcare professionals and providers with plan-level formulary data to support more-informed patient conversations.  

"We are always looking for ways to broaden our impact on patients and the people who care for them," Frank Harvey, CEO of Surescripts, said in a press release. "Our acquisition of ActiveRADAR underscores our commitment to optimizing our network solutions with even more comprehensive clinical and cost data available at the point of prescribing."

"Together, we can make it simpler and faster to get patients started on the best medication for them," Harvey added.

ActiveRADAR (formerly RxTE Health) offers evidence-based, formulary-specific, and medically accepted use-specific therapeutic alternatives. The health IT also provides corresponding dosage strengths, quantities, and plan-specific patient and health plan costs.

"We are very pleased to have reached this agreement, which will allow ActiveRADAR to have a direct impact on improving medication adherence as well as patient and provider engagement," said Dave Teckman, former CEO of ActiveRADAR.

"Our analytical processes target and prioritize savings opportunities to minimize member disruption and maximize savings, which ultimately improves the patient experience and takes waste and costs out of the system," Teckman continued.

ActiveRADAR's clinical catalog covers more than 165 therapeutic categories, including more than 30 specialty drug categories and more than 33,000 drug pairs. The IT solution has led to reduced costs for employers and employees by 15 to 20 percent.

"Providing faster access to insights and optimizing the value delivered by our data are two of our biggest priorities, so we're thrilled to have the ActiveRADAR team joining Surescripts," said Lynne Nowak, MD, chief data & analytics officer of Surescripts.

"With access to their extensive catalog of therapeutic alternatives data, we can reduce drug spend and help provide more alternatives when deploying prescription pricing information to providers," Nowak noted.